Core Insights - JD Health hosted the "Second Conference on Integration and Innovation in the Field of Mental Health" in Wuhan, highlighting its commitment to mental health services [1] - The new insomnia treatment drug, Daridorexant, achieved sales of over 5,000 boxes within 20 days of its launch [1] - JD Pharmacy launched a "Sleep Care Center" that integrates professional consultation, medication guidance, and health education to provide personalized sleep health services [1] Product Approval and Market Expansion - Daridorexant has received approvals in Europe, Switzerland, the UK, the US, Canada, and Japan, with the Chinese National Medical Products Administration approving it for market entry on June 20, 2025 [1] - The drug is indicated for the treatment of adult insomnia and is not classified under the "Controlled Psychotropic Substances" list [1] Future Development Plans - JD Health plans to continue promoting the integration of mental health and sleep medicine, enhancing collaboration with medical institutions and experts [1] - The company aims to improve service models to provide better sleep service experiences for users [1]